L
Lukas C. Amler
Researcher at Genentech
Publications - 100
Citations - 11788
Lukas C. Amler is an academic researcher from Genentech. The author has contributed to research in topics: Cancer & Pertuzumab. The author has an hindex of 44, co-authored 100 publications receiving 10731 citations. Previous affiliations of Lukas C. Amler include Bristol-Myers Squibb & Memorial Sloan Kettering Cancer Center.
Papers
More filters
Journal ArticleDOI
Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib
David A. Eberhard,Bruce E. Johnson,Lukas C. Amler,Audrey Goddard,Sherry Heldens,Roy S. Herbst,William L. Ince,Pasi A. Jänne,Thomas Januario,David H. Johnson,Pam Klein,Vincent A. Miller,Michael A. Ostland,D. Ramies,Dragan Sebisanovic,Jeremy Stinson,Yu R. Zhang,Somasekar Seshagiri,Kenneth J. Hillan +18 more
TL;DR: EGFR mutations may be a positive prognostic factor for survival in advanced NSCLC patients treated with chemotherapy with or without erlotinib, and may predict greater likelihood of response.
Journal ArticleDOI
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
David R. Gandara,Sarah M. Paul,Marcin Kowanetz,Erica B. Schleifman,Wei Zou,Yan Li,Achim Rittmeyer,Louis Fehrenbacher,Geoff Otto,Christine Malboeuf,Daniel S. Lieber,Doron Lipson,Jacob Silterra,Lukas C. Amler,Todd Riehl,Craig Cummings,Priti S. Hegde,Alan Sandler,Marcus Ballinger,David Fabrizio,Tony Mok,David S. Shames +21 more
TL;DR: It is shown that high bTMB is a clinically actionable biomarker for atezolizumab in NSCLC, and a blood-based DNA sequencing assay to infer tumor mutational burden in the absence of tumor biopsy predicts response to PD-L1 blockade in patients with non-small-cell lung cancer.
Journal ArticleDOI
Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts.
Yudi Pawitan,Judith Bjöhle,Lukas C. Amler,Anna-Lena Borg,Suzanne Egyhazi,Per Hall,Xia Han,Lars Holmberg,Fei Huang,Sigrid Klaar,Edison T. Liu,Lance D. Miller,Hans Nordgren,Alexander Ploner,Kerstin Sandelin,Peter M. Shaw,Johanna Smeds,Lambert Skoog,Sara Wedrén,Jonas Bergh +19 more
TL;DR: A subset of 64 genes was found to give an optimal separation of patients with good and poor outcomes, and the signature associated with prognosis and impact of adjuvant therapies was identified.
Journal ArticleDOI
Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy
Howard A. Burris,Hope S. Rugo,Svetislava J. Vukelja,Charles L. Vogel,Rachel A. Borson,Steven A. Limentani,Elizabeth Tan-Chiu,Ian E. Krop,Richard Alan Michaelson,Sandhya Girish,Lukas C. Amler,Maoxia Zheng,Yu Waye Chu,Barbara Klencke,Joyce O'Shaughnessy +14 more
TL;DR: T-DM1 has robust single-agent activity in patients with heavily pretreated, HER2-positive MBC and is well tolerated at the recommended phase II dose, with no dose-limiting cardiotoxicity.
Journal ArticleDOI
Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL
Klaus W. Wagner,Elizabeth Punnoose,Thomas Januario,David A. Lawrence,Robert M. Pitti,Kate Lancaster,Dori Lee,Melissa von Goetz,Sharon Yee,Klara Totpal,Ling Huw,Viswanatham Katta,Guy Cavet,Sarah G. Hymowitz,Lukas C. Amler,Avi Ashkenazi +15 more
TL;DR: A new link between death-receptor O-glycosylation and apoptotic signaling is uncovered, providing potential predictive biomarkers for Apo2L/TRAIL-based cancer therapy.